Skip to main content
SpringerLink
Log in

Antiretroviral Therapy and Drug Resistance in HIV-2 Infection

  • Living reference work entry
  • First Online:
Encyclopedia of AIDS

  • 418 Accesses

Definition

This entry reports on the susceptibility of HIV-2 to antiretroviral drugs and debates about the management of antiretroviral therapy in HIV-2-infected patients.

Introduction

Human immunodeficiency virus type 2 (HIV-2) is known to be less pathogenic and far less prevalent than HIV type 1 (HIV-1). However, HIV-2 affects an estimated 1–2 million people in West Africa (Gottlieb et al. 2008). HIV-2 has a lower infectivity than HIV-1, which is likely to be related to lower viral RNA levels. Even though its rate of progression is slower than HIV-1 infection, with a greater proportion of long-term nonprogressors (Thiebaut 2010), HIV-2-infected patients may develop advanced immunodeficiency and experience adverse clinical events.

Most antiretroviral drugs have been designed for HIV-1 and may not provide optimal viral suppression of HIV-2 infection. Furthermore, no randomized trials have assessed when and how to treat HIV-2-infected patients. The natural resistance of HIV-2 to...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Benard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, et al. ANRS CO5 HIV-2 cohort study group. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients. AIDS. 2009;23(9):1171–3.

    Article  PubMed  CAS  Google Scholar 

  • Benard A, van Sighem A, Taieb A, Valadas E, Ruelle J, Soriano V, et al. Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: the ACHIEV2E Collaboration Study Group. Clin Infect Dis. 2011;52(10):1257–66.

    Article  PubMed  CAS  Google Scholar 

  • Borrego P, Calado R, Marcelino JM, Bartolo I, Rocha C, Cavaco-Silva P, et al. Baseline susceptibility of primary HIV-2 to entry inhibitors. Antivir Ther. 2012;17(3):565–70.

    Article  PubMed  CAS  Google Scholar 

  • Boyer PL, Clark PK, Hughes SH. HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors. J Virol. 2012;86(10):5885–94.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Damond F, Benard A, Balotta C, Böni J, Cotten M, Duque V, et al. ACHI(E)V(2E) Study Group. An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study. J Clin Microbiol. 2011;49(10):3491–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Descamps D, Damond F, Matheron S, Collin G, Campa P, Delarue S, et al. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen. J Med Virol. 2004;74:197–201.

    Article  PubMed  CAS  Google Scholar 

  • DHSS. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Department of Health and Human Services. 14 October 2011; pp. 1–167. (Last updated March 27, 2012) athttp://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf

  • Drylewicz J, Eholie S, Maiga M, Zannou DM, Sow PS, Ekouevi DK, et al. International epidemiologic Databases to Evaluate AIDS (IeDEA) West Africa collaboration. First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaboration. AIDS. 2010;24(7):1043–50.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • EPF. Comparison of vertical human immunodeficiency virus type 2 and human immunodeficiency virus type 1 transmission in the French prospective cohort. The HIV Infection in Newborns French Collaborative Study Group. Pediatr Infect Dis J. 1994;13:502–6.

    Google Scholar 

  • Gilleece Y, Chadwick DR, Breuer J, Hawkins D, Smit E, McCrae LX, et al. BHIVA guidelines subcommittee. British HIV association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. HIV Med. 2010;11(10):611–9.

    Article  PubMed  CAS  Google Scholar 

  • Gottlieb GS, Eholié SP, Nkengasong JN, Jallow S, Rowland-Jones S, Whittle HC, et al. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS. 2008;22(16):2069–72.

    Article  PubMed  PubMed Central  Google Scholar 

  • Jallow S, Alabi A, Sarge-Njie R, Peterson K, Whittle H, Corrah T, et al. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. J Clin Microbiol. 2009;47(7):2200–8.

    Article  PubMed  PubMed Central  Google Scholar 

  • Landman R, Damond F, Gerbe J, Brun-Vezinet F, Yeni P, Matheron S. Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients. AIDS. 2009;23(3):426–8.

    Article  PubMed  Google Scholar 

  • Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G, et al. ANRS CO5 HIV2 Cohort Study Group. CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort. AIDS. 2006;20(3):459–62.

    Article  PubMed  Google Scholar 

  • Ntemgwa ML, Toni T, Brenner BG, Oliveira M, Asahchop EL, Moisi D, et al. Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2. Antimicrob Agents Chemother. 2009;53:708–15.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  • Reid P, MacInnes H, Cong ME, Heneine W, Garcia-Lerma GJ. Natural resistance of human immunodeficiency virus type 2 to zidovudine. Virology. 2005;336:251–64.

    Article  PubMed  CAS  Google Scholar 

  • Thiebaut R, Matheron S, Taieb A, Brun-Vezinet F, Chêne G, Autran B. Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort. AIDS. 2010;25:865–7.

    Article  Google Scholar 

  • Visseaux B, Hurtado-Nedelec M, Charpentier C, Collin G, Storto A, Matheron S, et al. Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool. J Infect Dis. 2012;205:111–20.

    Article  PubMed  CAS  Google Scholar 

  • WHO World Health Organisation Antiretroviral therapy in adults and adolescents – recommendations for a public health approach – 2010 revision. Available at: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. Accessed 6 Jan 2011.

  • Witvrouw M, Pannecouque C, Switzer MW, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004;9:57–65.

    PubMed  CAS  Google Scholar 

  • Yeni P. French guidelines for the treatment of HIV-infected adults with antiretroviral therapy. Flammarion. 2010; 238–46.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratoire de Virologie, Service de Microbiologie, Bichat-Claude Bernard Hospital and University, Paris, France

    Francoise Brun-Vezinet & Diane Descamps

  2. Service de Maladies Infectieuses et Tropicales, Bichat-Claude Bernard Hospital and University, Paris, France

    Sophie Matheron

Authors
  1. Francoise Brun-Vezinet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophie Matheron
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Diane Descamps
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francoise Brun-Vezinet .

Editor information

Editors and Affiliations

  1. Dept. Cell & Molecular Biology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA

    Thomas J. Hope

  2. Office of Graduate and Postdoctoral Studies, University of Miami, Miller School of Medicine, Miami, Florida, USA

    Mario Stevenson

  3. University of California, San Diego Dept. Pathology, La Jolla, California, USA

    Douglas Richman

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this entry

Cite this entry

Brun-Vezinet, F., Matheron, S., Descamps, D. (2013). Antiretroviral Therapy and Drug Resistance in HIV-2 Infection. In: Hope, T., Stevenson, M., Richman, D. (eds) Encyclopedia of AIDS. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9610-6_52-1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-9610-6_52-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, New York, NY

  • Online ISBN: 978-1-4614-9610-6

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation